T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

In a leap forward for genetic and biomedical research, two scientists at the University of Missouri have developed a powerful ...

Readers respond to an article about gene editing and object to cuts in research funding. Also: The Covid vaccine; Senator ...